Trace metal dynamics in zooplankton from the Bay of Bengal during summer monsoon

Trace metal (Fe, Co, Ni, Cu, Zn, Cd, and Pb) concentrations in zooplankton from the mixed layer were investigated at 8 coastal and 20 offshore stations in the western Bay of Bengal during the summer monsoon of 2003. The ecotoxicological importance of trace metal uptake was apparent within the Bay of Bengal zooplankton. There was a distinct spatial heterogeneity of metals, with highest concentrations in the upwelling zones of the southeast coast, moderate concentrations in the cyclonic eddy of the northeast coast, and lowest concentrations in the open ocean warm gyre regions. The average trace metal concentrations (μg g^?1) in coastal zooplankton (Fe, 44894.1 ± 12198.2; Co, 46.2 ± 4.6; Ni, 62.8 ± 6.5; Cu, 84.9 ± 6.7; Zn, 7546.8 ± 1051.7; Cd, 46.2 ± 5.6; Pb, 19.2 ± 2.6) were higher than in offshore zooplankton (Fe, 3423.4 ± 681.6; Co, 19.5 ± 3.81; Ni, 25.3 ± 7.3; Cu, 29.4 ± 4.2; Zn, 502.3 ± 124.3; Cd, 14.3 ± 2.9; Pb, 3.2 ± 2.0). A comparison of average trace metal concentrations in zooplankton from the Bay of Bengal showed enrichment of Fe, Co, Ni, Cu, Zn, Cd, and Pb in coastal zooplankton may be related to metal absorption from primary producers, and differences in metal concentrations in phytoplankton from coastal waters (upwelling zone and cyclonic eddy) compared with offshore waters (warm gyre). Zooplankton showed a great capacity for accumulations of trace metals, with average concentration factors of 4 867 929 ± 569 971, 246 757 ± 51 321, 337 180 ± 125 725, 43 480 ± 11 212, 1 046 371 ± 110 286, 601 679 ± 213 949, and 15 420 ± 9201 for Fe, Co, Ni, Cu, Zn, Cd, and Pb with respect to dissolved concentrations in coastal and offshore waters of the Bay of Bengal. © 2009 Wiley Periodicals, Inc. Environ Toxicol, 2009.     

Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer

Extensive research within the last two decades has revealed that most chronic illnesses, including cancer, diabetes, and cardiovascular and pulmonary diseases, are mediated through chronic inflammation. Thus, suppressing chronic inflammation has the potential to delay, prevent, and even treat various chronic diseases, including cancer. Various nutraceuticals from fruits, vegetables, vitamins, spices, legumes, and traditional Chinese and Ayurvedic medicine have been shown to safely suppress proinflammatory pathways; however, their low bioavailability in vivo limits their use in preventing and treating cancer. We describe here the potential of nanotechnology to fill this gap. Several nutraceuticals, including curcumin, green tea polyphenols, coenzyme Q, quercetin, thymoquinone and others, have been packaged as nanoparticles and proven to be useful in “nanochemoprevention” and “nano-chemotherapy”.     

First report of Salmonella enterica serotype paratyphi A azithromycin resistance leading to treatment failure

The prevalence of Salmonella enterica serotype Paratyphi A infection is increasing, and multidrug resistance is a well-recognized problem. Resistance to fluoroquinolones is common and leads to more frequent use of newer agents like azithromycin. We report the first case of azithromycin resistance and treatment failure in a patient with S. Paratyphi A infection.     

Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3)

The molecular basis of Glanzmann thrombasthenia (GT) was studied in 40 families from southern India. Of 23 identified mutations (13 in the alphaIIb (ITGA2B) gene and 10 in the beta3 (ITGB3) gene), 20 were novel and three were described previously. Three mutations in the beta3 gene-p.Leu143Trp (Leu117Trp), p.Tyr307Stop (Tyr281Stop), and p.Arg119Gln (Arg93Gln)-were detected in 12, three, and two families, respectively, with definite founder effects observed for the first two mutations. Alternative splicing was predicted in silico for the normal variant and a missense variant of the beta3 gene, and for 10/11 frameshift or nonsense mutations in alphaIIb or beta3. The prediction was confirmed experimentally for a c.2898_2902dupCCCCT mutation in exon 28 of the alphaIIb gene that induced exon skipping. Seven out of nine missense mutations substituted highly conserved amino acids buried in the proteins' cores, predicting structural abnormalities. Among these, a beta3 substitution, p.Cys39Gly (Cys13Gly) was found to cause intracellular degradation of the beta3 subunit, in contrast to previous findings that mutations at Cys435, the partner of Cys13 in a disulfide bond, cause constitutive activation of alphaIIbbeta3. The two patients with a beta3 Arg93Gln mutation had normal clot retraction, consistent with a recent finding that this substitution is associated with normal surface expression of alphaIIbbeta3. In conclusion, this study demonstrates that a variety of mutations account for GT in southern Indian patients, provides new insights into mRNA splicing, and highlights the role of specific amino acids in structure-function correlations of alphaIIbbeta3.     

Tuned-aperture computed tomography for detection of induced mid-buccal/lingual alveolar bone defects

BACKGROUND: The detection of bone loss in mid-buccal and lingual crests is impossible using conventional radiographs because of the superimposition of overlying anatomy and lack of three-dimensional information. The purpose of this study was to compare the diagnostic efficacy of tuned-aperture computed tomography (TACT) and conventional two-dimensional direct digital radiography (DDR) in an in vitro environment. METHODS: A total of 45 mandibular molars had 0.8-mm lesions on mid-buccal/lingual crestal areas. Half of the sites received defects, whereas the other half served as controls. Nine DDR images were used to generate TACT slices that were further subjected to iterative restoration (TACT-IR). Eight observers used a confidence rating scale to record diagnoses. Receiver operating characteristic (ROC) analysis was done, and areas under the curves were computed (A(z)) as indicators of diagnostic accuracy. Analysis of variance (ANOVA) was used to test for effects of observer, imaging modality, and location on the detection of lesions. RESULTS: TACT-IR performed significantly better than DDR. There was a significant difference in the accuracy of diagnosis based on observers (P <0.001). CONCLUSION: TACT-IR appears to be the imaging modality of choice for the detection of small osseous changes on crestal bone in mid-buccal/lingual sites.     

Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer

Proper management of prostate cancer patients is highly dependent on the spread of the disease. High expression levels of the androgen receptor (AR) in prostate tumor offer a target for identifying cancer metastasis. We investigated the use of nonsteroidal AR ligands for receptor-mediated imaging as a diagnostic tool for prostate cancer staging. Compound S-26 [S-3-(4-fluorophenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-iodophenyl)-propionamide]was identified from a series of iodinated ether-linked derivatives of bicalutamide due to its high-AR binding affinity of 3.3 nM (which is similar to testosterone and approximately 25% of the binding affinity of dihydrotestosterone) in an in vitro competitive binding assay using rat prostate cytosol. Furthermore, S-26 exhibited a greater binding affinity (K(i) = 4.4 nM) in a whole-cell binding assay using COS-7 cells transfected with human AR than testosterone (K(i) = 32.9 nM) and dihydrotestosterone (K(i) = 45.4 nM). We also confirmed that sex hormone-binding globulin (SHBG), a plasma protein that binds steroids with high affinity, does not bind with S-26. Cotransfection studies with the estrogen, progesterone, and glucocorticoid receptor indicated that S-26 does not cross-react with other members of the steroid hormone receptor family. The nonsteroidal structure, high-AR binding affinity, specificity, and lack of binding to SHBG indicate that S-26 exhibits favorable properties for further development as an imaging agent for prostate cancer.     

Effects of insulin deprivation and treatment on homocysteine metabolism in people with type 1 diabetes

CONTEXT: Abnormal homocysteine metabolism may contribute to increased cardiovascular death in type 1 diabetes (T1DM). Amino acid metabolism is altered in T1DM. In vitro, insulin reduces hepatic catabolism of homocysteine by inhibiting liver transsulfuration. It remains to be determined whether methionine-homocysteine metabolism is altered in T1DM. OBJECTIVE: We sought to determine whether insulin deficiency during insulin deprivation or high plasma insulin concentration after insulin treatment alters homocysteine metabolism in T1DM. DESIGN: This was an acute interventional study with paired and comparative controls. SETTING: The study was conducted at a general clinical research center. PATIENTS AND INTERVENTION: We used stable isotope tracers to measure methionine-homocysteine kinetics in six patients with T1DM during insulin deprivation (I-) and also during insulin treatment (I+) and compared them with nondiabetic controls (n = 6). MAIN OUTCOME MEASURES: Homocysteine kinetics (transmethylation, transsulfuration, and remethylation) were from plasma isotopic enrichment of methionine and homocysteine and (13)CO(2). RESULTS: T1DM (I-) had lower rates of homocysteine-methionine remethylation (P < 0.05 vs. control and I+). In contrast, transsulfuration rates were higher in I- than controls and I+ (P < 0.05). Insulin treatment normalized transsulfuration and remethylation (P < 0.05 vs. I- and P > 0.8 vs. control). Plasma homocysteine concentrations were lower in T1DM (P < 0.05 vs. control during both I- and I+), which may be explained by increased homocysteine transsulfuration. Thus, significant alterations of methionine-homocysteine metabolism occur during insulin deprivation in humans with T1DM. CONCLUSIONS: Insulin plays a key role in the regulation of methionine-homocysteine metabolism in humans, and altered homocysteine may occur during insulin deficiency in type 1 diabetic patients.